The relationship between serum total testosterone and prostate cancer (PCa) risk is controversial. The hypothesis that faster age-related reduction in testosterone is linked with increased PCa risk remains untested. We conducted our study at a tertiary-level hospital in southeast of the USA, and derived data from the Medical Registry Database of individuals that were diagnosed of any prostate-related disease from 2001 to 2015. Cases were those diagnosed of PCa and had one or more measurements of testosterone prior to PCa diagnosis. Controls were those without PCa and had one or more testosterone measurements. Multivariable logistic regression models for PCa risk of absolute levels (one-time measure and 5-year average) and annual change in testosterone were respectively constructed. Among a total of 1,559 patients, 217 were PCa cases, and neither one-time measure nor 5-year average of testosterone was found to be significantly associated with PCa risk. Among the 379 patients with two or more testosterone measurements, 27 were PCa cases. For every 10 ng/dL increment in annual reduction of testosterone, the risk of PCa would increase by 14% [adjusted odds ratio, 1.14; 95% confidence interval (CI), 1.03-1.25]. Compared to patients with a relatively stable testosterone, patients with an annual testosterone reduction of more than 30 ng/dL had 5.03 [95% CI: 1.53, 16.55] fold increase in PCa risk. This implies a faster age-related reduction in, but not absolute level of serum total testosterone as a risk factor for PCa. Further longitudinal studies are needed to confirm this finding.
Introduction
Prostate cancer (PCa) is the most commonly diagnosed solid organ cancer and the second leading cause of cancer death among men in the USA. 1 PCa represents a predominant threat to the life of men, especially for those aged 50 and older. Despite the recent advancements in both basic and translational research, 2,3 mechanisms, particularly androgenrelated mechanisms underpinning prostate carcinogenesis remains poorly understood. As a result, the development and implementation of evidence-based strategies for PCa prevention, early diagnosis and treatment have been greatly hindered. 4 It has been well established that human prostate gland depends on testosterone for its development, functioning and homeostasis, 5 and most PCa cells also depend on testosterone for growth, 6 however, the causal role played by testosterone in prostate carcinogenesis remains just a hypothesis (androgen hypothesis). 7 Although supported by several early studies, [8] [9] [10] this hypothesis has been questioned more frequently in recent years. Some studies found no association between serum testosterone and PCa risk; [11] [12] [13] many others showed the association as negative; 14, 15 while another group of studies revealed that the relationship between testosterone and PCa risk depends on the grade of PCa phenotypes. 16, 17 Collectively, for the association between testosterone and PCa risk, no consensus conclusion has been reached. Although it has been demonstrated that serum testosterone level in males falls substantially with aging, especially after the age of 40, 18, 19 evidence in both human and animal studies suggests that benign prostate tissues, to certain extent are able to maintain the intra-prostatic androgen at functional level, potentially by increasing the expression of androgen receptors and androgen biosynthesis enzymes. 20 This adaptation would intensify when the age-related decline in androgen level accelerates after age 40. 21 But when the adaptation reaches limit of the compensatory capabilities of prostatic cells, mutation rates and malignant evolution processes may markedly increase. 22 Thus, it is reasonable to hypothesize that it is the age-related decline, rather than absolute level of serum testosterone that contributes to prostate carcinogenesis. Although this hypothesis has been proposed by one previous study, 23 it remains untested. In our study, we explored the relationship between serum testosterone and risk of PCa using patients' data from a tertiary hospital. Absolute levels of and age-related changes in serum testosterone were analyzed separately to demonstrate which one is associated with increased risk of PCa.
Material and Methods

Study population and sample
Our study targeted patients with any prostatic disease. We derived data from the Medical Registry Database of a tertiary-level hospital in southeast of the USA. The records were linked with medical visits, hospitalizations, drug prescriptions, lab results and medical diagnoses. Patients from 2001 to 2015 were screened for eligibility. A patient was included as case if he was diagnosed of PCa and had at least one measurement of serum total testosterone prior to the first PCa diagnosis. If a patient was not diagnosed of PCa and had at least one measurement of serum total testosterone prior to the most recent diagnosis of benign prostatic diseases (BPD), he was included as a control. With this criterion, 217 PCa patients and 1,342 BPD patients were included, yielding a total sample of 1,559 patients. To test the association between testosterone levels and PCa, one-time measure (n 5 1,559) and 5-year average of testosterone (n 5 1,159) were analyzed, respectively. To test the association between change in testosterone and PCa risk, data of 379 patients were analyzed, including 27 PCa patients and 352 BPD patients.
Outcome variable
The outcome of interest was newly diagnosed PCa. PCa diagnosis was determined based on medical registry database using the International Classification of Disease, Ninth Revision (ICD-9) with malignant neoplasm of prostate code 185 and carcinoma in situ of prostate code 233.4. For PCa patients, the first diagnosis of PCa was used as the outcome. For non-cancer patients with BPD, the most recent diagnosis of BPD was used as the outcome. BPD diagnosis was also determined using ICD-9 codes (Supplementary Table S1 ).
Serum level of testosterone
To provide robust evidence, two measures were used to assess levels of testosterone (ng/dL): one-time measure was the level measured most recently prior to outcome diagnosis; 5-year average measurement was the arithmetic mean of all the measurements within 5 years prior to outcome diagnosis. The former was analyzed among all the patients, and the latter was analyzed among patients with at least one testosterone measurement within 5 years prior to outcome diagnosis. To provide adequate information, the two testosterone measures were analyzed as both continuous and in quintiles. Preliminary analysis indicated that the mean duration between the most recent testosterone measurement and outcome diagnosis was 3.2 years with standard deviation (SD) of 3.4. To control for potential confounding, this duration was included in multivariable analyses.
Annual change in testosterone level
Annual change in total testosterone (ng/dL per year) was analyzed among patients with two or more testosterone measurements prior to outcome diagnosis. For patients with only two testosterone measurements, change was calculated by subtracting the first measure from the second measure, and then divided by the time interval between the two measures. For patients with more than two measurements, annual change for each patient was computed by first regressing testosterone levels to time durations (in year) from when the testosterones were measured to outcome diagnosis, then taking the beta regression coefficient as the measure of annual change. Likewise, the annual change was analyzed as both continuous and categorical variable. For the categorical measure, three groups were defined: Reduction group with testosterone decline of >30 ng/dL per year (annual change <230 ng/dL), Relatively Stable group with changes between 230 and 30 ng/dL per year, and Increase group with testosterone increase in >30 ng/dL per year (annual change >30 ng/dL). The categorization was determined based on frequency distribution of the estimated annual changes in testosterone. In addition to duration from the most recent testosterone What's new? While serum testosterone levels in males decline markedly with age, particularly after age 40, risk of prostate cancer increases. Hypotheses have suggested a causal relationship, though whether serum testosterone levels are related to prostate cancer risk remains uncertain. In this analysis of absolute serum testosterone levels (one-time measure and 5-year average) and age-related annual changes in serum total testosterone, higher age-related annual reductions, rather than absolute testosterone levels, was associated with increased prostate cancer risk. The findings support a role for testosterone reduction in prostate cancer and suggest that slowing age-related testosterone decline may be relevant to prostate cancer prevention.
measure to outcome diagnosis (mean 5 1.9 years, SD 5 2.4), duration between the first and most recent testosterone measures (mean 5 5.4 years, SD 5 3.4) was also included in multivariable analysis to control for potential confounding.
Covariates
In addition to testosterone, we also assessed other potential influential factors for PCa, including age at outcome diagnosis (<65 and 65 years), race (black, white and others), cigarette smoking status at the first hospital admission (current, former and never), BMI at the first hospital admission (<25, 25 to <30 and 30 kg/m 2 ), PCa family history (yes/no), most recently measured prostate specific antigen (PSA) level (ng/mL), average frequency of PSA testing per year from the first hospital admission to outcome diagnosis, personal disease histories of BPD (yes/no), hypertension (yes/no) and diabetes (yes/no), as well as usage of testosterone supplementary therapy (yes/no) and finasteride (yes/no) by outcome diagnosis.
Statistical analysis
Characteristics of our study sample were assessed using descriptive statistical methods, including mean, SD and proportions. v 2 test (for categorical variables) and Student's t-test (for continuous variables) were used to compare sample differences. To assess the associations between testosterone (including levels and changes) and PCa, a bivariate analysis was conducted first to compare testosterone between PCa patients and BPD patients. Results of the bivariate analysis were further verified using two multivariable logistic regression models, one for testosterone being analyzed as a continuous measure and another for testosterone as a categorical measure. Covariates included in the multivariable analysis were those significant in bivariate analysis with p 0.20 and those although not significant in bivariate analysis but have well-known effect on PCa and/or testosterone level (age, race and PCa family history, testosterone supplementary therapy, finasteride use). Among the patients in the annual testosterone change analysis, those taking testosterone supplementary therapy were all distributed in BPD group. For the validity of model fit, testosterone supplementary therapy was thus not included in the multivariable model of annual testosterone change. But no association between annual change in testosterone and the therapy (yes/no) was found (p 5 0.908) even after adjusting for age, race and BMI. Adjusted odds ratios (AORs) with 95% confidence intervals (CIs) and p-values were reported, with p < 0.05 (two-sided) as statistically significant. All statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
Ethics
This study has been performed in accordance with the Declaration of Helsinki. The research protocol has been approved by University of Florida's Institutional Review Board (#IRB201600047).
Results
Characteristics of study participants
A total of 1,559 patients were included in our study, the median age was 67 (range, . Of the total sample, 217 (13.9%) were PCa patients and 1,342 (86.1%) were BPD patients; 171 (11.0%) were black and 1,016 (65.2%) were white. v 2 and t-test indicated that patients with PCa differed from patients with BPD in many aspects (Table 1 
Association between one-time measure of serum total testosterone and risk of PCa
In bivariate analysis among the 1,559 patients, Student's ttest indicated that one-time measure of testosterone was significantly lower in PCa patients than that in BPD patients (361.9 vs. 386.4 ng/dL, p 5 0.039). The difference became non-significant when testosterone was analyzed in quintiles using v 2 test (p 5 0.365) ( Table 2 ). In multivariable logistic regression analysis controlling for covariates, no significant association between one-time measurements of testosterone, whether as continuous or in quintiles, and PCa risk was found (Table 3 ). In addition, PSA level and average frequency of PSA testing per year were found to be positively associated with PCa risk, and overweight was associated with decreased PCa risk.
Association between 5-year average serum total testosterone and risk of PCa A total of 1,159 patients were included in this analysis, among which 172 (14.8%) were PCa patients and 987 (85.2%) were BPD patients. Student's t-test indicated that the 5-year average testosterone level of PCa patients was lower than that of BPD patients (345.2 vs. 384.8 ng/dL, p 5 0.002). When testosterone was analyzed in quintiles using v 2 test, the difference between the two groups became marginally nonsignificant (p 5 0.052) ( Table 2) . After controlling for covariates in multivariable logistic regression analysis, no significant association between 5-year average testosterone and PCa risk was observed, regardless whether the average testosterone was analyzed as continuous or in quintiles. Other factors found to be significantly associated with PCa risk were PSA level and average frequency of PSA testing per year (Table 4) .
Association between annual change in serum total testosterone and risk of PCa
Among the 379 patients with two or more measurements of testosterone, 27 (7.1%) were PCa patients and 352 (92.9%) were BPD patients. On average, PCa patients had an annual Cancer Epidemiology Increase group had a lower PCa risk, although no statistical significance was observed. In addition, smoking was found to be independently associated with decreased PCa risk, and higher PSA was associated with increased PCa risk ( Table 5 ).
The independent associations between serum total testosterone and risk of PCa from the three perspectives of one-time measure of, 5-year average of, and annual change in testosterone are summarized in Figure 1 .
Discussion
The relationship between serum testosterone and PCa risk has been a consistently pursued research question since the pioneering study conducted by Huggins and Hodges 7 in 1941 which suggested a direct correlation between circulating testosterone levels and PCa progression. Our study, for the first time, found direct epidemiological evidence supporting the Abbreviations: AOR, adjusted odds ratio; PCa, prostate cancer; BPD, benign prostatic diseases; PSA, prostate specific antigen. Five-year average of serum total testosterone was analyzed as a continuous variable in Model I and categorical (quintile) in Model II. Covariates included in the models were those significant in bivariate analysis with p 0.20 and those although not significant in bivariate analysis but have well-known effect on PCa and/or testosterone level (age, race, PCa family history, testosterone supplementary therapy and finasteride use).
hypothesis that it is faster age-related reductions, rather than absolute levels in serum testosterone that significantly affects the risk of PCa.
In our study, one-time measure and 5-year average of serum testosterone levels, whether analyzed as continuous or categorical, were not found to be significantly associated with PCa after adjusting for other covariates (Tables 3 and 4 , Fig. 1 ). Despite different study designs (i.e., control group consisted of BPD patients in our study, whereas most prior studies used general population as control group), these results agree with a considerable number of prior studies. [11] [12] [13] For this observation, various explanations have been suggested, such as lack of prospective study design with sufficient power, 12 or serum testosterone is simply unrelated to PCa development. 4 However, another potential explanation that PCa development is more influenced by dynamic changes rather than absolute levels in serum testosterone has not been reported previously.
According to the findings of our study, for every 10 ng/dL increment in the annual reduction of testosterone, the risk of PCa would increase by 14% [AOR, 1.14; 95% CI, 1.03-1.25]. Compared to patients with a relatively stable testosterone level, patients in the group with an annual testosterone reduction of >30 ng/dL had 5.03 [95% CI: 1.53, 16 .55] fold increase in PCa risk (Table 5 , Fig. 1 ). This discovery is in line with current endocrinology research in prostate. The homeostasis in normal prostate is maintained by the interaction between stromal and epithelial cells through a paracrine mechanism. In the presence of adequate testosterone, the binding of testosterone to stromal androgen receptor (AR) can produce andromedins, which will promote proliferation of basal epithelial cells by binding to their receptors. However, binding of testosterone to luminal epithelial AR can counteract the effects of andromedins and promote differentiation of luminal cells. 24 When a dramatic age-related decrease in serum testosterone is present, the paracrine mechanism of AR action will be replaced by an emergent autocrine mechanism, leading to selection of pre-neoplastic cells that are less dependent on signals from stromal and basal cells. This could initiate uncontrolled AR-driven proliferation of luminal cells. 25 In addition, it is established that a dramatic decline in serum testosterone could increase the expression of AR and androgen biosynthesis genes, 20 which will jointly drive chromosomal rearrangements and alter transcriptional programs. 26, 27 This can in turn alter the DNA sites to which AR binds and further increase the probability of prostate carcinogenesis. Similar findings have been reported in prostate stem cells in murine model study. 28 This finding is also in accordance with some epidemiological evidence. According to one study 29 based on National Health and Nutritional Examination Survey (NHANES) data, black males, compared to white males, have significantly higher peak levels of testosterone during young age, but the difference diminishes with aging and completely disappears after age 60. It indicated that the testosterone levels in blacks Cancer Epidemiology decrease faster with increasing age compared to that in white. This result supports the findings of our study, and may jointly in part explain the observed racial disparities in PCa risk. 23 If confirmed, this finding has important implications for PCa pathogenesis study, PCa prevention and early diagnosis. First, it will contribute to clarification of the perennial question of relationship between serum testosterone and PCa risk, and thus may help explain the observed associations between some proven influential factors (age, race, physical activity, et al.) and PCa risk. Based on this knowledge, measures that can slow age-related declines in serum testosterone can potentially be applied to prevent PCa, such as engaging in more physical activity, controlling body weight, supplementing zinc and preventing vitamin D deficiency, et al. 30, 31 These will be of particular importance from the age of 40, when serum testosterone is about to have an obvious decline. 29, 32 Second, this will potentially endow positive significance on testosterone replacement therapy (TRT) in preventing PCa, as TRT can effectively smooth the age-related decline in testosterone if given at appropriate time. This is in line with a recent prospective study reporting that TRT among hypogonadal men had preventive effect against PCa.
14 However, more confirmatory studies of TRT safety are needed. Third, this finding also has great significance regarding PCa early diagnosis by potentially providing a new biomarker for prostate biopsy. Facing the widely debate on application of PSA for PCa detection, 33, 34 adding the agerelated testosterone change into the current indicator system of PCa screening would make important clinical significance.
Our study has several strengths. To our knowledge, this is the first empirical study supporting the hypothesis of agerelated reductions in testosterone as a risk factor for PCa. Results of our study were robust since we simultaneously analyzed both absolute levels (one-time measure and 5-year average) of and annual changes in total testosterone in one study, and also both continuous and categorical measures of testosterone were considered. Second, the data used in this analysis were extracted from medical registry, thereby avoiding the probability of recall bias, which is inherent to traditional retrospective case-control studies.
Meanwhile, our study has several limitations. First, the intervals between testosterone measurements were not same for all patients, and the sample size of patients having two or more testosterone measurements in our study was limited. Bias cannot be ruled out without a formally designed longitudinal study. Second, the controls were drawn from BPD patients rather than the general population, this would reduce the generalizability of our study conclusion. Third, although our findings are consistent with much previous evidence, in light of inevitable bias in observational study, more research at multi-scales is needed to elucidate the involved biological mechanisms to provide more convincing evidence. Fourth, findings from previous studies suggested the relationship between testosterone and PCa risk may depend on the grade of PCa phenotypes, 16, 17 but in our study, 47.0% (102/ 217) of the PCa cases had Gleason score missing, due to that Gleason score was recorded as free-text medical notes in the database and we were only able to retrieve a small portion of the notes through text mining. Among the 115 cancer cases having Gleason score, we respectively constructed logistic regression model for high-grade (Gleason score 7) vs. lowgrade prostate cancer (Gleason score < 7) of one-time measure (high-grade n 5 69, low-grade n 5 46), 5-year average (highgrade n 5 52, low-grade n 5 35) of, and annual change (highgrade n 5 7, low-grade n 5 10) in testosterone level adjusting for age, race, BMI, PCa family history, the most recently measured PSA level, and average frequency of PSA testing per year, no statistical significance of the testosterone measures was found. As the under-power of this analysis, we showed the results in Supplementary Table S2 . Besides, some recent studies have shown that in low-intermediate risk PCa, highrisk patterns of tumor upgrading was also associated with increased testosterone levels, 35, 36 thus the roles of testosterone change in differing-grade prostate cancer development and progression are all important directions for future research.
Despite these limitations, our study for the first time provided empirical data supporting the testosterone-reduction hypothesis in explaining the relationship between testosterone and PCa risk. It implies that relevant measures that can smooth age-related reduction in testosterone level have potentials in preventing PCa, but more rigorously designed observational and experimental studies are needed to confirm this finding.
